M0010 – Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services

Long description

Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services

Short description

Eom meos payment

Pricing indicator

00 Not separately priced by Part B (bundled, not covered or Part A only)

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

P7B Oncology - other

Added

April 1, 2023

Last change

January 1, 2026 – No change

Nearby M codes

• M0001 – Advancing cancer care mips value pathways
• M0002 – Optimal care for kidney health mips value pathways
• M0003 – Optimal care for patients with episodic neurological conditions mips value pathways
• M0004 – Quality care for patients with neurological conditions mips value pathway
• M0005 – Value in primary care mips value pathway
• M0064 – Brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders
• M0075 – Cellular therapy
• M0076 – Prolotherapy
• M0100 – Intragastric hypothermia using gastric freezing
• M0201 – Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home
• M0220 – Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring
• M0221 – Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
• M0222 – Intravenous injection, bebtelovimab, includes injection and post administration monitoring